Open AccessSevere pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
Author(s) -
Saleh Mostafa F. M.,
Saunthararajah Yogen
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1221
Subject(s) - medicine , decitabine , pyoderma gangrenosum , regimen , myelodysplastic syndromes , myeloid leukemia , malignancy , deoxycytidine , dermatology , cancer , gemcitabine , bone marrow , disease , biochemistry , gene expression , chemistry , dna methylation , gene
Key Clinical Message Pyoderma gangrenosum ( PG ) is a morbid necrotizing neutrophilic dermatoses for which current treatments are inadequate. Here, we describe the use of a novel noncytotoxic regimen of the deoxycytidine analog decitabine to treat underlying myeloid malignancy causing PG , to thereby produce safe and effective resolution of extensive PG .